Decreased PTPN12 expression associated with poor prognosis in HCC
As reported in PLoS ONE, the expression of PTPN12 was decreased in hepatocellular carcinoma tissue samples compared with adjacent normal tissues. Furthermore, decreased PTPN12 expression was associated with tumor recurrence, decreased cancer-specific survival, and decreased recurrence-free survival.
KIT mutations associated with poor prognosis in GISTs
Based on a meta-analysis (18 studies; n=1487) reported in the World Journal of Surgical Oncology, KIT mutations in patients with gastrointestinal stromal tumors (GISTs) are associated with larger tumors (> 5 cm), higher mitotic activity (> 5), more frequent recurrences (OR = 2.06), more frequent metastases (OR = 2.77), and worse 3-year overall survival (OR = 0.47) compared to patients with PDGFRA mutations or wild-type.
SIRT3 expression improves prognosis in gastric cancer
As reported in the World Journal of Surgery, SIRT3 expression improves the prognosis in patients with gastric cancer (n=221). Specifically, the 5-year OS was 51.2% and 39.1% in patients who do and do not express SIRT3, respectively. The 5-year DFS was 49.6% and 38.0% in patients who do and do not express SIRT3, respectively. Patients who do not express SIRT3 are characterized by increased poor cellular differentiation, increased diffuse-type Lauren’s histology, and increases scirrhous-type stromal reactions, suggesting the SIRT3 functions as a tumor suppressor.